Participation in cancer treatment clinical trials is a key measure for delivery of quality cancer care, yet adult trial participation in the U.S. remains under 3%, with even lower participation rates among ethnic and racial minorities and people over 65. Whether focusing on studies sponsored by the National Cancer Institute or industry, institutions often struggle in isolation to achieve efficient and effective accrual.
The Commission on Cancer’s 2015 guidelines dictate higher accrual rates for all cancer treating institutions, so it is more important than ever to use effective accrual practices that are grounded in evidence. Unfortunately, there are few evidence-based practices to help sites achieve higher accrual rates. ENACCT is creating this evidence through its leadership of the Cancer Clinical Trial Collaborative Learning Network (CCTCLN). The CCTCLN is built upon the successful work of the National Pilot Collaborative completed in 2012. (Read more here). The goal of the CCTCLN is to further the goal of the Pilot: to identify practical, patient-centered approaches to increase accrual overall and, in particular, for ethnic /racial minorities and people over 65.
ENACCT is now accepting applications for the next generation of this network to assist cancer centers and community oncology practices in becoming more effective and efficient in their approaches to recruitment, accrual and retention. (See www.enacct.org for more details.). The Learning Network Can Help Cancer Centers and Community Oncology Practices by:
Institutions who join this Network will participate in a unique opportunity for improving their accrual practices in a cost-effective manner. Applications are open now and are due June 21 2013. (See www.enacct.org for more details.)
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.